*Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.» Read More
May 19- Ophthotech Corp said it could potentially receive over $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. Ophthotech's shares rose as much as 29 percent in trading after the bell.
*Working on more tiered pricing after deal with Egypt. LONDON, April 8- Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.